Authors: Mike Clements, Cristina Altrocchi, Devon Guerrelli, Adam P. Hill, Nikki Posnack, Chris Strock, and Takashi Yoshinaga
Axion BioSystems, GA, USA; Johnson & Johnson, Belgium; Children’s National Hospital, DC, USA; Victor Chang Cardiac Research Institute, Australia; Cyprotex, MA, USA; Eisai Co., Ltd, Japan
Presented at ISSCR 2025 on June 11th, 2025 by Mike Clements, PhD
Cardiac stem cell models are transforming research and discovery—but a lack of standardized criteria to assess functional activity can lead to inconsistent results. Over the last decade, the multielectrode array (MEA) assay has become a popular tool for characterizing hiPSC-cardiomyocyte (CM) batches, studying disease models, screening therapeutics, and evaluating drug-induced cardiotoxicity.
The goal of this project is to set the minimum acceptance criteria for a spontaneous beating wild type hiPSC-ventricular cardiomyocyte field potential assay for compound testing and/or disease modeling.
Axion iPSC Model Standards (AIMS)
AIMS seeks to leverage the expertise of key opinion leaders in the field and set minimum acceptance criteria for stem-derived model activity when used in Maestro MEA assays.
